Another example is the phase III OlympiA trial, which included patients with HER2-negative early breast cancer with high-risk clinicopathological features and germline BRCA1 or BRCA2 pathogenic mutations who had received local treatment and neoadjuvant or adjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.